Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.
PFE - Pfizer Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$28.50
DETAILS
HIGH:
$31.00
LOW:
$26.00
MEDIAN:
$28.50
CONSENSUS:
$28.50
UPSIDE:
2.24%
Stock News
Pfizer: The 10-Year Is At 5%, And I'm Still Buying This 6%+ Yield
Pfizer remains a compelling income play, offering a 6.22% yield and trading at 9.3x 2026 consensus EPS amid a rising-rate environment. PFE's non-COVID portfolio is growing 5% operationally, with robust pipeline activity and $1.5B ahead of the original 2026 base business guidance. Management targets $9.7B in cost savings by 2029, supporting dividend coverage through the patent cliff and enabling R&D investment.
Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?
Pfizer has made significant progress in addressing some of its challenges. However, the company still has a rocky road ahead.
Is Pfizer an Excellent Dividend Stock to Buy?
Pfizer (PFE +0.07%) has experienced unprecedented circumstances in the previous decade.
3 Dividend Stocks to Buy and Hold for 10 Years
They have a knack for increasing their dividends even when facing challenges.
2 High-Yield Dividend Stocks to Buy and 1 to Avoid
Pfizer's free cash flow is not covering its dividend, and the company faces a patent cliff. Energy Transfer is one of the biggest beneficiaries of strong natural demand coming from the AI data center build-out.
Pfizer's Dividend Yield Is Enormous. But Is the Payout Still Growing?
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
How Much Do You Really Need Invested to Replace a $130,000 Salary With Dividends?
The yield you chase to replace a six-figure salary determines far more than how much capital you need. It quietly sets your exposure to leverage, dividend cuts, and an NAV that can quietly bleed out before you notice.
Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.
Pfizer's management remains firmly committed to maintaining the dividend. The company's growth portfolio is performing well.
How a Roth IRA Can Keep Thousands More of Your High-Yield Dividend Income Compounding
Where you hold a high-yield dividend stock matters almost as much as which one you pick, and for ordinary-income payers like BDCs and REITs, the wrong account quietly erodes a portion of every distribution before it ever compounds.
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S. All Stars 2026 Conference on Tuesday, September 22, 2026 at 11:50 a.m. BST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors.
Bank of America Corp DE Buys New Stake in Pfizer Inc. $PFE
Bank of America Corp DE purchased a new stake in Pfizer Inc. (NYSE: PFE) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,588,109 shares of the biopharmaceutical company's stock, valued at approximately $1,049,602,000. Bank of America Corp DE owned about
Pfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage
Pfizer NYSE: PFE Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining COVID-19-related demand and upcoming losses of exclusivity for certain products.
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
PFE faces COVID revenue declines and a patent cliff, but new products, acquisitions and a strong pipeline could fuel growth from 2029.
4 High-Yield Dividend Stocks Worth Having in Your Roth IRA
Not every high-yield dividend stock belongs in a Roth IRA, but these four generate the kind of ordinary income that makes tax-free compounding matter most. One has raised its payout 60 times in 56 years, another locks tenants into leases stretching nearly four decades into the future.
Pfizer's 6% Yield Masks a Fragile Dividend Story
Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error.
Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines
The drugmaker has targeted air-traffic control fees in a dispute with Poland and Romania.
Price Targets
Pfizer price target raised to $30 from $28 at HSBC
$30.00
(was $27.78)
HSBC
Pfizer price target lowered to $31 from $35 at Guggenheim
$31.00
(was $26.20)
Guggenheim
Pfizer downgraded to Hold from Buy at HSBC
$28.00
(was $24.32)
HSBC
UBS Reiterates Neutral Rating on Pfizer (PFE)
$27.00
(was $26.34)
Michael Yee
·
UBS
Pfizer price target raised to $26 from $25 at Wolfe Research
$26.00
(was $25.96)
Alexandria Hammond
·
Wolfe Research
Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive'
$27.00
(was $27.05)
Terence Flynn
·
Morgan Stanley
BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data
$30.00
(was $26.48)
Evan David Seigerman
·
BMO Capital
RBC Capital Starts Pfizer (PFE) at Underperform
$25.00
(was $27.14)
Trung Huynh
·
RBC Capital
Pfizer initiated with an Underweight at Barclays
$25.00
(was $26.86)
Emily Field
·
Barclays
Pfizer downgraded to Neutral from Outperform at Daiwa
$27.00
(was $27.73)
Narumi Nakagiri
·
Daiwa
Pfizer price target raised to $27 from $24 at Cantor Fitzgerald
$27.00
(was $25.88)
Cantor Fitzgerald
Pfizer assumed with a Neutral at UBS
$25.00
(was $25.43)
UBS
Pfizer (PFE) PT Lowered to $24 at Wolfe Research
$24.00
(was $25.53)
Alexandria Hammond
·
Wolfe Research
Pfizer price target lowered to $28 from $32 at Morgan Stanley
$28.00
(was $25.89)
Morgan Stanley
Pfizer price target raised to $29 from $28 at HSBC
$29.00
(was $25.33)
Rajesh Kumar
·
HSBC
Pfizer price target raised to $35 from $33 at Guggenheim
$35.00
(was $25.17)
Guggenheim
Goldman Sachs on Pfizer (PFE): 'Challenging Crosscurrents As Focus Shifts To 2026 Guidance Next Month'
$26.00
(was $24.23)
Asad Haider
·
Goldman Sachs
Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera
$30.00
(was $24.45)
Courtney Breen
·
Bernstein
Pfizer price target lowered to $32 from $33 at Morgan Stanley
$32.00
(was $25.24)
Morgan Stanley
Pfizer drug pricing deal 'mostly performative,' says BofA
$28.00
(was $27.16)
Tim Anderson
·
UBS